1. It's like a publicly traded "blank check" company, similar to how Bill Ackman's Pershing Square Tontine Holdings (PSTH) operated, whose entire purpose is to acquire a private business and bring it public.

2. Think of it as a publicly listed investment vehicle that doesn't have its own products or services yet; its sole purpose is to merge with an existing private company, much like a specialized private equity fund searching for an acquisition target.

3. Essentially, it's a publicly traded shell company, akin to a holding company that has raised capital but is still in the process of identifying and acquiring its core operating asset.

• Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI): An investigational medical device designed to reduce hyperinflammation in critically ill patients with AKI who require continuous renal replacement therapy.
• Selective Cytopheretic Device (SCD) for Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI): An investigational medical device being developed to prevent or mitigate acute kidney injury in patients undergoing cardiac surgery.
• Selective Cytopheretic Device (SCD) for Chronic Kidney Disease (CKD): An investigational medical device exploring potential applications in chronic inflammatory conditions associated with chronic kidney disease.

Threats for SeaStar Medical (symbol: ICU), based on the provided company description as a Special Purpose Acquisition Company (SPAC):

• Declining investor interest in Special Purpose Acquisition Companies (SPACs). The broader market sentiment has shifted away from SPACs due to factors such as poor post-merger performance of many SPAC-acquired companies and increased skepticism from institutional investors. This trend threatens the ability of a SPAC like ICU to secure investor funding for its intended merger or to attract a desirable private company as a target, as the appeal of going public via a SPAC diminishes.
• Increasing regulatory scrutiny and potential changes in SPAC regulations. Regulatory bodies, particularly the U.S. Securities and Exchange Commission (SEC), have indicated a focus on tightening oversight and potentially implementing new rules for SPACs. This emerging regulatory environment could make the process of identifying a target and completing a SPAC merger significantly more complex, costly, and time-consuming, thereby reducing the viability and attractiveness of the SPAC business model.

• QUELIMMUNE (SCD-Pediatric) for Pediatric Acute Kidney Injury (AKI) with Sepsis: The estimated annual addressable market in the U.S. is approximately $100 million, targeting about 4,000 patients.
• NEUTRALIZE-AKI (SCD for Adult AKI): The estimated annual addressable market in the U.S. is between $4.5 billion and $6.3 billion, impacting approximately 210,000 adult patients annually.
• Cardiorenal Syndrome (without Left Ventricular Assist Device - LVAD): This represents a U.S. market opportunity estimated at $13.1 billion to $17.4 billion, with an annual patient population of 580,000.
• Adult Acute Respiratory Distress Syndrome (ARDS): The U.S. market size for this indication is projected to be $4.5 billion to $6.0 billion, targeting 200,000 patients.
• Adult Hepatorenal Syndrome: The estimated U.S. market size is $1.1 billion to $1.5 billion, with 50,000 patients.
• Cardiorenal Syndrome with LVAD: This indication has an estimated U.S. market size of $1.4 billion to $1.8 billion, involving 60,000 patients.
• Systemic Inflammatory Response in Adult and Pediatric Cardiac Surgery Patients: This potential market includes approximately 45,000 patients annually, comprising 15% of 300,000 adult cardiac surgery patients and one-third of 40,000 pediatric congenital heart surgery patients.

SeaStar Medical (symbol: ICU) anticipates several key drivers of future revenue growth over the next 2-3 years, primarily centered on the expansion of its existing product, the advancement of its pipeline for larger markets, and the exploration of new indications for its core technology.

1. Expansion of QUELIMMUNE Commercialization in Pediatric AKI: SeaStar Medical is focused on broadening the adoption of its FDA-approved QUELIMMUNE therapy for life-threatening acute kidney injury (AKI) in critically ill pediatric patients. The company aims to expand its customer base by adding new top-ranked children's medical centers, with a goal to include 15 additional centers in 2026, effectively doubling its total number of sites and increasing order depth. This strategy is expected to drive significant revenue growth, with approximately $2 million in net product revenue anticipated from QUELIMMUNE in 2026. Recent financial results have shown a fourfold sequential increase in QUELIMMUNE revenue, driven by increased adoption and repeat orders from existing customers, alongside the acquisition of new nationally recognized children's hospitals.

2. Advancement and Potential Approval in the Adult AKI Market (NEUTRALIZE-AKI Trial): A major driver of future revenue growth is the progress and eventual approval of the NEUTRALIZE-AKI pivotal trial, which evaluates the company's Selective Cytopheretic Device (SCD) therapy in adult AKI patients. This market is significantly larger than the pediatric AKI market, with an estimated annual U.S. market opportunity of $4.5 billion. SeaStar Medical aims to complete enrollment in the NEUTRALIZE-AKI trial by the end of 2026 and plans to initiate a modular Premarket Approval (PMA) process. The therapy has received Breakthrough Device Designation from the FDA, which is intended to expedite the approval process for life-saving novel devices. Successful trial results and subsequent FDA approval could be a transformative event for the company.

3. Expansion into New Indications and Pipeline Development: SeaStar Medical is leveraging its proprietary SCD technology platform for applications beyond AKI. The company is exploring further indications for its SCD technology. Notably, it has initiated the NEUTRALIZE-CRS clinical trial to treat patients with acute Chronic Heart Failure (CHF) suffering from cardiorenal syndrome (CRS) who are awaiting Left Ventricular Assist Device (LVAD) implantation. Additionally, SeaStar Medical has secured multiple FDA Breakthrough Device Designations, including for chronic dialysis, further broadening the long-term growth potential and market opportunities for its SCD technology. The company plans to seek additional Humanitarian Use and Breakthrough Device Designations to support patients with various life-threatening conditions.

Share Issuance

• SeaStar Medical became publicly listed on Nasdaq in October 2022 through a business combination with LMF Acquisition Opportunities, Inc., a transaction that provided access to capital markets.
• On June 20, 2025, the company announced a public offering of common stock and warrants, which was expected to raise approximately $3.39 million for corporate expenses.
• A registered direct offering on July 10, 2025, for 5,242,464 shares of common stock, alongside warrants, was expected to generate gross proceeds of approximately $4 million.

Inbound Investments

• SeaStar Medical completed a business combination with LMF Acquisition Opportunities, Inc., a special purpose acquisition company, in October 2022, a transaction that implied an enterprise value of approximately $85 million for SeaStar Medical.
• The Dow Chemical Company Pension Plans, as existing investors of SeaStar Medical, committed to further participate in the business combination transaction through a PIPE (Private Investment in Public Equity) investment.

Capital Expenditures

• Net proceeds from a registered direct offering of approximately $4 million in July 2025 were intended for general corporate purposes, including potential additions to working capital and capital expenditures.